Urgent care in mild COVID patients, Randomised Controlled Trials Budesonide vs Usual Care:
URGENT CARE In mild COVID patients, Randomised Controlled Trials Budesonide vs Usual Care:
– significanttly less patients required urgent care in group using budesonide compared to usual care (relative risk reduction 91% for budesonide), in the STOIC trial (small number of participants, aged 18+). (1)
– in PRINCIPLE, a much larger trial with patients at risk of deterioration (older/with co-morbidities), there was a (non-significant) indication of reduced hopitalisation or death in the budesonide group, although superiority was not demonstrated. (2)
Categories:
COVID
Entry Date:
21/09/2021
Source 1 Name:
Ramakrishnan S, Nicolau DV, Jr., Langford B, Mahdi M, Jeffers H, Mwasuku C, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine. 2021;9(7):763-72.
Source 1 URL:
Source 2 Name:
Yu L-M, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. The Lancet. 2021;398(10303):843-55.
Source 2 URL:
Source 3 Name:
Source 3 URL:
Source 4 Name:
Source 4 URL:
Source 5 Name:
Source 5 URL:
Source 6 Name:
Source 6 URL: